Chonyang Albert, MD
Advanced Heart Failure and Transplant Cardiology · Cleveland, OHNPI 1194084202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,270 of the $3,667 with a category attached, or 89.2%. 23 manufacturers reported payments, led by Abbott at 44.0% of the total. 2025 is the largest year on record at $1,792, more than ten times the $172 reported in 2019. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in OH, where the typical reported total is $4,421.
Across 73 payments — averaging $50.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Abiomed$786
- Eurofins Viracor, LLC$417
- Daxor Corporation$124
- Atricure, Inc.$84
- Cvrx, Inc.$78
- plus $566 from 17 others
What the payments were for
- Travel & lodging$1334%
- Food & beverage$3,27089%
- Education$2647%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 18 | $1,613 |
| Abiomed | 17 | $786 |
| Eurofins Viracor, LLC | 2 | $417 |
| Daxor Corporation | 1 | $124 |
| Atricure, Inc. | 3 | $84 |
| Cvrx, Inc. | 4 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Teleflex LLC | 1 | $60 |
| One Lambda, Inc. | 2 | $51 |
| Pfizer | 3 | $51 |
| Actelion Pharmaceuticals US, Inc. | 3 | $48 |
| Merck | 2 | $37 |
| Bayer | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Ancora Heart, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $24 |
| Analog Devices Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,140
- Impella$239
- MitraClip$180
- BVA-100$124
- CardioMEMS HF System$112
How this compares
$3,667 in reported general payments places this provider in the 45th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 132 | $147,595 |
| JardianceEmpagliflozin | 79 | $86,163 |
| EliquisApixaban | 36 | $43,556 |
| FarxigaDapagliflozin Propanediol | 40 | $32,393 |
| Sirolimus | 16 | $5,949 |
| Tacrolimus | 20 | $2,537 |
| Metoprolol Succinate | 90 | $1,935 |
| Eplerenone | 13 | $1,043 |
| Torsemide | 29 | $876 |
| Spironolactone | 97 | $851 |
| Atorvastatin Calcium | 71 | $703 |
| Carvedilol | 68 | $702 |
| Rosuvastatin Calcium | 38 | $570 |
| Digoxin | 21 | $393 |
| Potassium Chloride | 19 | $386 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $17 | $86,16379 claims |
| PfizerEliquis | $51 | $43,55636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Cleveland
- Andres Carmona RubioCleveland$27K
- Pavan BhatCleveland$16K
- Robert MontgomeryCleveland$9K
- Sanjeeb BhattacharyaCleveland$7K
- Tuoyo Mene-AfejukuCleveland$6K
- Ran LeeCleveland$5K
- Amanda VestCleveland$4K
- Leon ZhouCleveland$3K
- Karlee HoffmanCleveland$2K
- Michael HillCleveland$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.